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Abstract
The TP53 gene has been the subject of intense research since the realisation
that inactivation of this gene is common to most cancer types. Numerous
publications have linked TP53 mutations in general or at specific locations to
patient prognosis and therapy response. The findings of many studies using
general approaches such as immunohistochemistry or sequencing are
contradictory. However the detection of specific mutations, especially those
occurring in the structurally important L2 and L3 zinc binding domains, which
are the most common sites of TP53 mutations, have been linked to patient
prognosis and more strongly to radiotherapy and chemotherapy resistance in
several major cancers. In this study, the TI-SPR-1 surface plasmon
resonance system and Texas Instruments SpreetaTM chips were used to
develop a DNA biosensor based on thiolated probes complementary to these
domains. The sensors were able to detect these mutations in both
oligonucleotides and PCR products with normal and mutant TP53 DNA, but
the difference in hybridisation signal was small. Preliminary experiments to
enhance the signal using Escherichia coli mismatch repair proteins, MutS and
single strand binding protein were carried out. It was found that MutS was
unable to bind to mismatch oligonucleotides, but single strand binding protein
was able to bind to single stranded probes which had not hybridised to the
target, resulting in a 3-fold increase in the sensitivity of the biosensor. While
further work needs to be carried out to optimise the system, these preliminary
experiments indicate that the TI-SPR-1 can be used for the detection of
clinically relevant mutations in the TP53 gene and that the sensitivity can be
increased significantly using single strand binding protein. This system has a
number of advantages over current mutation detection technologies, including
lower cost, ease of sensor preparation and measurement procedures,
technical simplicity and increased speed due to the lack of need for gel
electrophoresis.
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1. Introduction
The human genome mapping project has facilitated and driven the
development of many new technologies for molecular diagnostic applications,
including immunoassays, protein assays, genetic analysis and gene
expression studies (Gander et al., 2003). These tools have the potential to be
used and have in some cases already been used widely in medical
diagnostics, particularly in cancer diagnostics. It is highly desirable to be able
to determine the presence of cancer in asymptomatic patients, how
aggressive the tumour is, whether there are metastases, the preferred
treatment, effectiveness of surgery, the response to chemotherapy and
recurrence of tumours (Gander et al., 2003). A major area where genetic
tests could be applied is in prognosis and therapy selection and to that end a
large amount of research has been carried out to link genes and genetic
mutations to cancer pathogenesis and response to treatment. The human
TP53 gene is a prime example of this, as extensive research has revealed
that this gene is the most frequently mutated gene in human cancers and it is
thought to be inactivated or function abnormally in the majority of tumours.
This can be observed by either increased concentration of p53 protein,
complete absence of p53 protein or the presence of genetic mutations or
mutated forms of p53 protein. Not only does mutation disable the normal
TP53 functions, including cell cycle arrest and induction of apoptosis in
response to DNA damage and inhibition of angiogenesis, but some mutations
can also provide tumours with growth advantages and resistance to
chemotherapy and ionising radiation. Although the prevalence of different
TP53 mutations varies between cancer types and tumour subclasses, the
most common mutations occur at “hotspot” codons on the gene. These
mutations can be detected either by analysing the p53 protein structure, the
level of p53 protein expression or all or part of the TP53 genetic sequence.
The advantage of full-length sequencing is that no mutations are missed, but
this procedure is time consuming. In addition, the quicker sequencing
methods and other mutation detection technologies are not always accurate,
are very technically demanding or have to be repeated using different
conditions to obtain maximum sensitivity. Short oligonucleotide probes can
be used in a number of ways to detect particular mutations with a high
sensitivity or can be combined with other probe sequences to rapidly detect
mutations at several sites at once. This technology is ideally suited to the
detection of gene mutations which can occur at a number of particular
codons, such as TP53 mutations.
A number of studies have found that mutations in specific structural domains
of the TP53 gene are linked to patient prognosis and response to specific
therapies and where there is sufficient evidence that this is the case a
clinician could use a diagnostic test to select the most appropriate treatment
for individual patients (Soussi & Béroud, 2001). The biological justification for
this, areas where it might be applied and the mutation detection technologies
currently available for this application, have recently been reviewed (Jiang et
al., 2004a).
The aim of this study was to investigate the potential of surface plasmon
resonance as a means of detecting point mutations in the TP53 gene with a
view to the development of sensors to detect mutations within the structurally
important and clinically significant regions where TP53 mutations occur. Such
a sensor could have value in both assessing prognosis and therapy selection
for cancer patients. We sought to show that the detection of single base
mutations in the TP53 gene using a surface plasmon resonance DNA
biosensor based on the Texas Instruments SpreetaTM system, could be
enhanced by the application of the mismatch binding protein MutS and single
stand binding protein.
2. Materials & Methods
The TI-SPR-1 (Texas Instruments, USA) optical biosensor system was used
with SpreetaTM sensor chips coated with thiol-immobilised DNA probes
(Sigma-Genosys, Cambridge, UK) in a flow cell format (see Figure 1) and
controlled by SpreetaTM software. The 28-mer DNA probes corresponded to
the structurally important L2 zinc binding domain of the TP53 gene (sequence
3'--HS-(CH2)6-CTCCAACACTCCGCGACGGGGGTGGTAC--5' and were used
to detect hybridisation of oligonucleotide probes (Sigma, Milan, Italy) identical
to both the normal TP53 sequence (5'--
GAGGTTGTGAGGCGCTGCCCCCACCATG--3') and the most common
mutation in this region, a (G  A SNP at codon 175) (5'--
GAGGTTGTGAGGCACTGCCCCCACCATG--3'). Sensor chips were
prepared by cleaning with ethanol followed by 10 minutes incubation in a
solution containing ethanol, 30% ammonia, and MilliQ water in a 1:1:5 ratio.
After drying the chips were inserted into the TI-SPR-1 and the flow cell
connected. Thiloated probe (1μM) in potassium phosphate buffer (KH2PO4,
pH 3.4) was then passed over the sensor surface for 2 hours at 5μl / minute,
followed by 1 hour exposure to 6-mercapto-1-hexanol in darkness at the same
flow rate. The chips were stored in flowing MilliQ water (2μl/minute) overnight
and exposed to hybridisation buffer for at least 30 minutes before use, in
order to obtain a stable baseline. The high reproducibility of chips produced
by this method has been demonstrated in previuosly reported work from our
group (Jiang et al., 2004).
Hybridisation was carried out by establishing a stable baseline in hybridisation
buffer and then flowing oligonucleotides (1μM) in hybridisation buffer over the
sensor surface for 5 minutes. This was followed by 3 minutes in hybridisation
buffer to compensate for the bulk effect of the probe solution and to wash
away any unbound material from the sensor surface. Finally the sensor was
regenerated by 2 minutes exposure to 25mM NaOH and returned to
immersion in hybridisation buffer in preparation for the next measurement. A
flow rate of 10μl/minute was used throughout. The hybridisation signal was
taken as the difference between the refractive index at the baseline and that
at the end of the 3 minute washing step. The mismatch binding protein MutS
and single strand binding protein (SSB) (Amersham Biosciences, Milan, Italy)
were applied after hybridisation to enhance the sensitivity to mutations. The
proteins were made up in similar solutions to those in other studies; MutS
(0.22μM) in MutS binding buffer ((50mM TRIS-HCl, 100mM KCl, 1mM
(EDTA), 1mM dithiotreitol (DTT), 5mM MgCl2, pH 7.4) and SSB (0.29μM) in
SSB binding buffer (50mM TRIS-HCl, 100mM KCl, 1mM EDTA, 1mM DTT,
5mM MgCl2, 0.005% TWEEN 20, pH 7.4). Measurements were carried out by
exposing the sensor to the protein for 15 minutes at a flow rate of 2μl/minute
following hybridisation The sensor was then washed in hybridisation buffer for
3 minutes at a flow rate of 2μl/minute and 9 minutes at 10μl/minute, with the
signal being recorded at the end of the 9 minute washing step. A negative
control experiment was carried out by applying SSB prior to the MutS to inhibit
MutS binding to single stranded DNA and DNA chain ends. In addition,
0.29μM bovine serum albumin (BSA) (Amersham Biosciences, Milan, Italy) in
MutS binding buffer was used as a negative control for all protein experiments
because it is a similar size to MutS, can adsorb strongly to bare gold surfaces
and exhibits no specific binding to any of the reagents used in this sensor
system. Figure 1 shows a diagram describing how these experiments can be
configured as a detection system.
3. Results
Our previous work has shown that the TI-SPR-1 is sensitive enough to detect
differences in hybridisation affinity caused by single nucleotide polymorphisms
(SNPs) and in particular those relating to TP53 mutations (Jiang et al.,
2004b). In this study, the mutant DNA sequence containing a single base
mutation produced a refractive index change (RIC) discernible from that of the
normal DNA sequence on any given SpreetaTM chip. However, this
difference was relatively small and slight variations between chips may
necessitate calibration of each individual chip for reliable routine use.
In this study MutS and SSB were applied in an attempt to enhance the
sensitivity so that clear cut-off points for RICs indicating the presence of a
TP53 mutation in the L2 zinc binding domain could be established. If applied
after hybridisation, MutS should give a higher RIC if a mutation is present than
if no mutation is present, since mutations create mismatched DNA
sequences. SSB should also give a higher RIC when a mutation is present,
because mutant DNA has a lower affinity for the immobilised DNA probes and
less hybridisation occurs, so there are more free probes on the sensor for the
protein to bind to. Application of SSB prior to MutS should not affect the
ability of MutS to bind to mismatches, but would prevent non-specific binding
of MutS to DNA probes and chain ends.
The results of these experiments (see Figure 2) show that when MutS was
applied directly after hybridisation there was no clear difference in binding
signal between mutant and normal DNA sequences. Furthermore there was
no MutS binding following the application of SSB. This indicates that MutS
was binding to either DNA chain ends or immobilised DNA probes, possibly
because the high density of immobilised probes on the sensor surface
prevented the relatively large MutS protein binding to mismatches. However,
there was a clear difference in SSB binding between mutant and normal DNA
and this difference was three times greater than the difference resulting from
the hybridisation signal alone.
The stability, optimum storage conditions and reproducibility of the sensor
were investigated in detail and it was found that it produced a stable baseline
through at least 50 regeneration cycles, high reproducibility of hybridisation
signal and could be stored for at least 1 night in flowing MilliQ water
(2μl/minute) with no significant loss in sensitivity (data not shown).
4. Discussion
The inability to detect mismatches using MutS protein in these experiments
indicates that when MutS was used alone it was binding either to the ends of
duplexes formed by hybridisation or to single stranded free probe, as was
observed in previous studies (Gotoh et al., 1997, Babic et al., 1996). The
second explanation would seem the more likely since the average signal
obtained with MutS applied to complementary oligonucleotide was higher than
when a mismatched sequence was used. This is supported by the very low
signal obtained with BSA, which showed that all the proteins were interacting
specifically with the immobilised probes and/or hybridised oligonucleotides, as
BSA adsorbs well to bare gold surfaces and indeed has been used as the
basis of an immobilisation procedure for SpreetaTM sensors (Kukansis et al.,
1999). We suggest that the relatively large (91kDa) MutS protein was unable
to reach hybridised DNA at the sensor surface due to the high density of
immobilised probes and so was unable to bind specifically to mismatches in
this case. MutY, a protein of the same family as MutS, has been used in a
solid phase assay for the detection of TP53 mutations (Lu & Hsu, 1992) and it
is possible that MutS could also be used in this application if the conditions
required for binding can be optimised.
The difference in signal between SSB binding with complementary and
mutant oligonucleotides was much greater than expected. This can be
explained by taking into consideration the fact that the hybridisation conditions
used were optimised to produce the maximum difference in oligonucleotide
binding and this difference would be amplified by the binding of SSB since this
protein is larger than the oligonucleotide strands and binds close to the sensor
surface. The SSB experimental data reported here is based on preliminary
tests and further investigation is required to establish the optimum
hybridisation conditions and SSB exposure parameters and to determine the
sensitivity with different concentrations of oligonucleotides and PCR products.
While the method is a little more complex and less reproducible than
monitoring hybridisation directly, it is still much simpler and quicker than many
of the mutation detection methods described by Nollau & Wagener (1997) and
the remaining difficulties could be resolved easily by the use of an automated
liquid handling system.
5. Conclusions
While the prognostic and therapeutic indications of TP53 mutations are still
subject to debate, in some cancer types clear patterns are emerging where
patient response to therapies which cause cancer cell apoptosis through the
TP53 pathway is considerably reduced when a TP53 gene mutation is
present. Current cancer research on the TP53 gene and P53 protein reveal
significant associations between mutations and patient outcomes when
mutations are present in the structurally important L2 and L3 zinc binding
domains in breast, colon, head and neck and lung cancer, wheras other types
of mutation are not associated with patient outcome at all or are specific to a
certain cancer type. The likelihood is that further studies into the significance
of TP53 mutations in other cancer types will reach similar conclusions.
Therefore at present a detection system for mutations in these specific
regions seems the best approach to develop a test with the widest possible
area of application.
In this study a region of the L2 zinc binding domain was chosen as a target
region as it was of appropriate length for the analysis and is the site of the
second most common mutation in the TP53 gene, a G-A substitution at codon
175. The demonstration of a successful mutation detection system using
probes corresponding to this mutation leads to the assumption that mutations
of different types throughout the L2 domain could also be detected, and this
will be verified in future work.
Overall, this study suggests that an optimised system based on the
application of SSB after hybridisation could be utilised in the detection of
these clinically relevant mutations. Such an approach has the advantage of
needing inexpensive equipment that would be relatively straightforward to
automate and could provide rapid results, with high sensitivity.
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Figure 2: Comparison of the effectiveness of the mutation detection methods
attempted in this study. Based on 4 hybridisation measurements, 2
measurements with MutS and MutS with SSB, and 4 measurements with SSB
alone.
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